Abstract
Summary
The Asia-Pacific sarcopenia treatment market is expected to reach USD 861,882.42 thousand by 2030 from USD 547,450.80 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030.
Market Segmentation:
Asia-Pacific Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Sarcopenia Treatment Market Dynamics
Driver
• Rising prevalence of sarcopenia
Restrain
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by key market players
Market Players:
Some of the key market players operating in the Asia-Pacific sarcopenia treatment market are:
• Abbott
• Nestlé Health Science (A subsidiary of Nestlé S.A.)
• Novartis AG
• Sanofi
• AstaReal Co., Ltd.
• Haleon Group of Companies
• BASF SE
• Fermenta Biotech Limited
• Healing Pharma India Pvt.Ltd
• Metagenics
• The Vitamin Company India
• Wellona Pharma
• Biophytis
• ImmunoForge Inc.
• ONCOCROSS CO., LTD.
• OPKO Health, Inc.
• Regeneron Pharmaceuticals Inc.
• DSM
Table of Contents
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF THE ASIA-PACIFIC SARCOPENIA TREATMENT MARKET 22
1.3.1 REST OF ASIA-PACIFIC 159
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 33
2.8 MARKET END USER COVERAGE GRID 34
2.9 DBMR MARKET POSITION GRID 35
2.10 VENDOR SHARE ANALYSIS 36
2.11 SECONDARY SOURCES 37
2.12 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTEL- 42
4.2 PORTER 43
5 REGULATIONS IN AUSTRALIA 44
6 MARKET OVERVIEW 45
6.1 DRIVERS 47
6.1.1 RISING PREVALENCE OF SARCOPENIA 47
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 47
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 48
6.2 RESTRAINTS 49
6.2.1 LACK OF STANDARDIZED DIAGNOSIS 49
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 50
6.3 OPPORTUNITIES 50
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 50
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 51
6.4 CHALLENGES 51
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 51
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 52
7 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 53
7.1 OVERVIEW 54
7.2 VITAMIN/DIETARY SUPPLEMENTS 57
7.2.1 VITAMIN SUPPLEMENTS 58
7.2.2 PROTEIN SUPPLEMENTS 58
7.2.3 FATTY ACID SUPPLEMENTS 58
7.2.4 CREATINE 58
7.2.5 WHEY PROTEINS 58
7.2.6 L-CARNITINE 58
7.2.7 SOY 58
7.2.8 BETA-ALANINE 58
7.2.9 OSTARINE 58
7.2.10 COLLAGEN PEPTIDES 59
7.2.11 LIGANDROL 59
7.2.12 BRANCH-CHAIN AMINO ACIDS 59
7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 59
7.2.14 MEDIUM CHAIN TRIGLYCERIDES 59
7.2.15 OTHERS 59
7.3 MEDICATIONS 60
7.3.1 OFF LABEL DRUGS 60
7.3.2 EMERGING DRUGS 60
- 7.3.2.1 ACE INHIBITORS 60
- 7.3.2.1.1 APPETITE STIMULANTS 61
- 7.3.2.1.2 ORAL ANTIDIABETIC DRUGS 61
- 7.3.2.1.3 OTHERS 61
- 7.3.2.1 ACE INHIBITORS 60
7.4 OTHERS 61
8 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE 62
8.1 OVERVIEW 63
8.2 PRIMARY SARCOPENIA 65
8.2.1 VITAMIN/DIETARY SUPPLEMENTS 66
8.2.2 MEDICATIONS 66
8.2.3 OTHERS 66
8.3 SECONDARY SARCOPENIA 66
8.3.1 VITAMIN/DIETARY SUPPLEMENTS 66
8.3.2 MEDICATIONS 66
8.3.3 OTHERS 67
9 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES 68
9.1 OVERVIEW 69
9.2 PRE-SARCOPENIA 71
9.3 SARCOPENIA 71
9.4 SEVERE SARCOPENIA 71
10 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 72
10.1 OVERVIEW 73
10.2 ORAL 75
10.3 INJECTABLES 75
10.4 OTHERS 76
11 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER 77
11.1 OVERVIEW 78
11.2 MALE 80
11.3 FEMALES 80
12 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER 81
12.1 OVERVIEW 82
12.2 HOSPITALS 84
12.2.1 PUBLIC 84
12.2.2 PRIVATE 84
12.3 SPECIALTY CLINICS 85
12.4 HOME HEALTHCARE 85
12.5 OTHERS 85
13 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 86
13.1 OVERVIEW 87
13.2 DIRECT TENDER 89
13.3 RETAIL SALES 90
13.3.1 HOSPITAL PHARMACIES 90
13.3.2 ONLINE PHARMACIES 90
13.3.3 OTHERS 90
13.4 OTHERS 90
14 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRIES 91
14.1 ASIA-PACIFIC 91
14.1.1 JAPAN 94
14.1.2 CHINA 99
14.1.3 SOUTH KOREA 104
14.1.4 INDIA 109
14.1.5 AUSTRALIA 114
14.1.6 SINGAPORE 119
14.1.7 THAILAND 124
14.1.8 MALAYSIA 129
14.1.9 INDONESIA 134
14.1.10 PHILIPPINES 139
14.1.11 VIETNAM 144
14.1.12 NEW ZEALAND 149
14.1.13 TAIWAN 154
15 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY 160
15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 160
16 SWOT ANALYSIS 161
17 COMPANY PROFILES 162
17.1 ABBOTT 162
17.1.1 COMPANY SNAPSHOT 162
17.1.2 REVENUE ANALYSIS 162
17.1.3 PRODUCT PORTFOLIO 163
17.1.4 RECENT DEVELOPMENT 163
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 164
17.2.1 COMPANY SNAPSHOT 164
17.2.2 REVENUE ANALYSIS 164
17.2.3 PRODUCT PORTFOLIO 165
17.2.4 RECENT DEVELOPMENT 165
17.3 NOVARTIS AG 166
17.3.1 COMPANY SNAPSHOT 166
17.3.2 REVENUE ANALYSIS 166
17.3.3 PRODUCT PORTFOLIO 167
17.3.4 PIPELINE PORTFOLIO 167
17.3.5 RECENT DEVELOPMENT 167
17.4 SANOFI 168
17.4.1 COMPANY SNAPSHOT 168
17.4.2 REVENUE ANALYSIS 168
17.4.3 PRODUCT PORTFOLIO 169
17.4.4 RECENT DEVELOPMENT 169
17.5 HALEON GROUP OF COMPANIES 170
17.5.1 COMPANY SNAPSHOT 170
17.5.2 REVENUE ANALYSIS 170
17.5.3 PRODUCT PORTFOLIO 171
17.5.4 RECENT DEVELOPMENT 171
17.6 ASTAREAL CO., LTD 172
17.6.1 COMPANY SNAPSHOT 172
17.6.2 PRODUCT PORTFOLIO 172
17.6.3 RECENT DEVELOPMENT 172
17.7 BASF SE 173
17.7.1 COMPANY SNAPSHOT 173
17.7.2 REVENUE ANALYSIS 173
17.7.3 PRODUCT PORTFOLIO 174
17.7.4 RECENT DEVELOPMENT 174
17.8 DSM 175
17.8.1 COMPANY SNAPSHOT 175
17.8.2 REVENUE ANALYSIS 175
17.8.3 PRODUCT PORTFOLIO 176
17.8.4 RECENT DEVELOPMENT 176
17.9 FERMENTA BIOTECH LIMITED 177
17.9.1 COMPANY SNAPSHOT 177
17.9.2 REVENUE ANALYSIS 177
17.9.3 PRODUCT PORTFOLIO 178
17.9.4 RECENT DEVELOPMENT 178
17.10 HEALING PHARMA INDIA PVT.IND 179
17.10.1 COMPANY SNAPSHOT 179
17.10.2 PRODUCT PORTFOLIO 179
17.10.3 RECENT DEVELOPMENT 179
17.11 METAGENICS 180
17.11.1 COMPANY SNAPSHOT 180
17.11.2 PRODUCT PORTFOLIO 180
17.11.3 RECENT DEVELOPMENT 180
17.12 THE VITAMIN COMPANY INDIA 181
17.12.1 COMPANY SNAPSHOT 181
17.12.2 PRODUCT PORTFOLIO 181
17.12.3 RECENT DEVELOPMENT 181
17.13 WELLONA PHARMA 182
17.13.1 COMPANY SNAPSHOT 182
17.13.2 PRODUCT PORTFOLIO 182
17.13.3 RECENT DEVELOPMENT 182
17.14 BIOPHYTIS 183
17.14.1 COMPANY SNAPSHOT 183
17.14.2 PIPELINE PORTFOLIO 183
17.14.3 RECENT DEVELOPMENT 183
17.15 IMMUNOFORGE INC 184
17.15.1 COMPANY SNAPSHOT 184
17.15.2 PIPELINE PORTFOLIO 184
17.15.3 RECENT DEVELOPMENT 184
17.16 ONCOCROSS CO., LTD 185
17.16.1 COMPANY SNAPSHOT 185
17.16.2 PIPELINE PORTFOLIO 185
17.16.3 RECENT DEVELOPMENT 185
17.17 OPKO HEALTH, INC 186
17.17.1 COMPANY SNAPSHOT 186
17.17.2 REVENUE ANALYSIS 186
17.17.3 PIPELINE PORTFOLIO 187
17.17.4 RECENT DEVELOPMENT 187
17.18 REGENERON PHARMACEUTICALS INC 188
17.18.1 COMPANY SNAPSHOT 188
17.18.2 REVENUE ANALYSIS 188
17.18.3 PIPELINE PORTFOLIO 189
17.18.4 RECENT DEVELOPMENT 189
18 QUESTIONNAIRE 190
19 RELATED REPORTS 193